中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu

Vol.41 No.1 (291 in total) Jan. 2025

Theme Issue: Functional Cure of Chronic Hepatitis B Executive 

Chief Editor: ZHUANG Hui

Peking University Health Science Center
Cover Content

 Previous Issue | Next Issue 

Display Method:
Editorial
Functional cure of chronic hepatitis B is not a dream
Hui ZHUANG
2025, 41(1): 2-6. DOI: 10.12449/JCH250101
Abstract(522) HTML (2015) PDF (1656KB)(182)
Abstract:
Functional cure of chronic hepatitis B （CHB） is defined as HBsAg<0.05 IU/mL and serum HBV DNA<10 IU/mL for at least 24 weeks after discontinuation of antiviral therapy. This requires suppression of HBV replication and reduction of viral antigen production， as well as restoration of immune resp...
Expert Forum
New drugs for the functional cure of hepatitis B: Focusing on antisense oligonucleotides and small interfering RNAs
Xieer LIANG, Zhihong LIU, Jinlin HOU
2025, 41(1): 7-14. DOI: 10.12449/JCH250102
Abstract(378) HTML (1408) PDF (716KB)(131)
Abstract:
Existing nucleos（t）ide analogues and pegylated interferon exhibit limited efficacy in the functional cure of hepatitis B. Recently， small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， have brought unprecedented breakthroughs in the functional cure of hepatitis B ...
How far is the functional cure of chronic hepatitis B from complete cure?
Na GAO, Zhiliang GAO
2025, 41(1): 15-23. DOI: 10.12449/JCH250103
Abstract(419) HTML (1312) PDF (1039KB)(165)
Abstract:
Functional cure is currently the ideal treatment endpoint for chronic hepatitis B （CHB） in China and globally. HBsAg seroclearance and HBV DNA that cannot be detected in peripheral blood for more than 24 weeks marks the regression of hepatitis B virus （HBV） infection. However， there is still a lack ...
Effect of hepatitis B virus integration on functional cure
Xiaoqi YU, Xinxin ZHANG
2025, 41(1): 24-29. DOI: 10.12449/JCH250104
Abstract(269) HTML (1533) PDF (618KB)(77)
Abstract:
Functional cure is currently recommended by guidelines as the ideal treatment goal for the prevention and treatment of chronic hepatitis B （CHB） in China and globally， and it is defined as sustained and undetectable serum HBsAg and HBV DNA， HBeAg clearance， and presence or absence of HBsAg seroconve...
Guideline
Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al
2025, 41(1): 30-40. DOI: 10.3760/cma.j.cn113884-20240814-00245
Abstract(287) HTML (1059) PDF (1162KB)(90)
Abstract:
Up to half of patients with hepatocellular carcinoma （HCC） in China are diagnosed at an advanced stage and often with a dismal prognosis. More effective treatment strategies are mandatory. In recent years， the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has shown...
An excerpt of non‑cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management (2024)
Junqi XIA, Zhe LYU, Chenghai LIU, Xingshun QI
2025, 41(1): 41-43. DOI: 10.12449/JCH250106
Abstract(221) HTML (1907) PDF (487KB)(65)
Abstract:
Recently， Asian Pacific Association for the Study of the Liver published the recommendations for the diagnosis and management of non-cirrhotic portal fibrosis （NCPF）/idiopathic portal hypertension （IPH）. The guidelines mainly elaborate on the definition， diagnosis， histological features， natural his...
Viral Hepatitis
Changes in renal function in chronic hepatitis B patients treated initially with entecavir versus tenofovir alafenamide fumarate and related influencing factors
Shipeng MA, Yanqing YU, Xiaoping WU, Liang WANG, Liping LIU, Yuliang ZHANG, Xin WAN, Shanfei GE
2025, 41(1): 44-51. DOI: 10.12449/JCH250107
Abstract(227) HTML (75) PDF (1093KB)(49)
Abstract:
Objective To investigate the influence of entecavir （ETV） versus tenofovir alafenamide fumarate （TAF） on renal function in previously untreated patients with chronic hepatitis B （CHB）. Methods A retrospective analysis was performed for the clinical data of 167 previously untreated CHB patients who r...
Liver histopathological features of HBeAg-negative patients in the indeterminate phase of low-viral-load chronic hepatitis B virus infection
Lulu ZHOU, Bing DONG, Jiejing XIN, Guanghua XU, Na LIU
2025, 41(1): 52-56. DOI: 10.12449/JCH250108
Abstract(143) HTML (69) PDF (740KB)(24)
Abstract:
Objective To investigate the liver histopathological features of HBeAg-negative patients in the indeterminate phase of low-viral-load chronic hepatitis B virus （HBV） infection. Methods A total of 271 patients with low-viral-load HBeAg-negative chronic HBV infection who underwent liver biopsy in Depa...
The level of HBV cccDNA in liver tissue and its clinical significance in patients in the convalescence stage of hepatitis B virus-related acute-on-chronic liver failure
Zhekai CAI, Long XU, Wenli LIU, Yingqun XIAO, Qingmei ZHONG, Wei ZHANG, Min WU
2025, 41(1): 57-62. DOI: 10.12449/JCH250109
Abstract(163) HTML (75) PDF (690KB)(26)
Abstract:
Objective To investigate the expression level of HBV cccDNA in patients in the convalescence stage of hepatitis B virus-related acute-on-chronic liver failure （HBV-ACLF） and its correlation with HBV markers and liver histopathological changes. Methods A total of 30 patients in the convalescence stag...
Fatty Liver Disease
Characteristics of cardiometabolic risk in patients with different subtypes of non-alcoholic fatty liver disease
Lili GAO, Yong WANG, Huafang YAN, Xiaoliang WANG, Yunfeng WANG
2025, 41(1): 63-68. DOI: 10.12449/JCH250110
Abstract(164) HTML (62) PDF (647KB)(22)
Abstract:
Objective To investigate the difference in the risk of cardiovascular diseases between patients with different subtypes of non-alcoholic fatty liver disease （NAFLD） from the perspective of metabolism， since cardiovascular events induced by metabolic disorders are the leading cause of death in NAFLD....
Liver Neoplasm
Efficacy of stereotactic body radiotherapy combined with sintilimab and bevacizumab in treatment of unresectable hepatocellular carcinoma
Teng ZHANG, Quan WANG, Wengang LI, Xuezhang DUAN
2025, 41(1): 69-74. DOI: 10.12449/JCH250111
Abstract(151) HTML (1503) PDF (1358KB)(26)
Abstract:
Objective To investigate the efficacy and safety of stereotactic body radiotherapy （SBRT） combined with sintilimab and bevacizumab in the treatment of patients with unresectable hepatocellular carcinoma （uHCC） and related prognostic factors. Methods A total of 42 patients with uHCC who underwent SBR...
Risk factors for concurrent hepatic hydrothorax before intervention in primary liver cancer and construction of a nomogram prediction model
Yuanzhen WANG, Renhai TIAN, Yingyuan ZHANG, Danqing XU, Lixian CHANG, Chunyun LIU, Li LIU
2025, 41(1): 75-83. DOI: 10.12449/JCH250112
Abstract(125) HTML (78) PDF (1292KB)(31)
Abstract:
Objective To investigate the influencing factors for hepatic hydrothorax （HH） before intervention for primary hepatic carcinoma （PHC）， and to construct and assess the nomogram risk prediction model. Methods A retrospective analysis was performed for the clinical data of 353 hospitalized patients who...
The distribution pattern of traditional Chinese medicine syndromes and influencing factors for primary liver cancer: An analysis of 415 cases
Zhiyao SHI, Xiaofei FAN, Yu GAO, Shaojian REN, Shiyu WU, Xixing WANG
2025, 41(1): 84-91. DOI: 10.12449/JCH250113
Abstract(150) HTML (65) PDF (765KB)(21)
Abstract:
Objective To investigate the influencing factors for traditional Chinese medicine （TCM） syndromes of primary liver cancer， and to provide a theoretical basis for the TCM syndrome differentiation and standardized treatment of liver cancer. Methods TCM syndrome differentiation was performed for 415 pa...
Effect of sorafenib and donafenib on the pharmacokinetics of ertugliflozin in rats
Yanru DENG, Gexi CAO, Bin YAN, Ying LI, Zhanjun DONG
2025, 41(1): 92-98. DOI: 10.12449/JCH250114
Abstract(130) HTML (59) PDF (1361KB)(16)
Abstract:
Objective To investigate the effect of sorafenib and donafenib on the pharmacokinetics of ertugliflozin in rats， and to provide a theoretical basis for drug combination in clinical practice. Methods A total of 24 male Sprague-Dawley rats were randomly divided into groups A， B， C， and D， with 6 rats ...
Other Liver Disease
Level of vitamin D in children with cholestatic liver disease and its clinical features
Ziyun GUO, Lina DU, Xiaoxuan XIE, Yan YANG
2025, 41(1): 99-103. DOI: 10.12449/JCH250115
Abstract(152) HTML (69) PDF (628KB)(22)
Abstract:
Objective To investigate vitamin D level in children with cholestatic liver disease， and to provide a theoretical basis for vitamin D supplementation therapy in children with this disease. Methods A total of 116 children with cholestatic liver disease who attended Department of Traditional Chinese M...
Changes in hemoglobin and related influencing factors in patients with liver failure undergoing artificial liver support therapy
Ying LIN, Li CHEN, Fei PENG, Jianhui LIN, Chuanshang ZHUO
2025, 41(1): 104-109. DOI: 10.12449/JCH250116
Abstract(138) HTML (1432) PDF (1037KB)(24)
Abstract:
Objective To investigate the changing trend of hemoglobin （Hb） and related influencing factors in patients with liver failure after artificial liver support system （ALSS） therapy. Methods A total of 106 patients with liver failure who were hospitalized and received ALSS therapy in our hospital from ...
Mechanism of action of thymic stromal lymphopoietin in a mouse model of acetaminophen-induced acute liver injury
Wenshang CHEN, Mingjing YIN, Jijin ZHU
2025, 41(1): 110-117. DOI: 10.12449/JCH250117
Abstract(134) HTML (66) PDF (2533KB)(18)
Abstract:
Objective To investigate the role and mechanism of thymic stromal lymphopoietin （TSLP） in a mouse model of acetaminophen （APAP）-induced acute liver injury. Methods A total of 16 wild-type （WT） male C57BL/6J mice were randomly divided into control group and APAP group， with 8 mice in each group， and ...
Biliary Disease
Clinical features of patients with recurrent primary common bile duct stones after cholecystectomy
Jianhui LU, Yongli LI, Ruifang GUO, Rongquan XUE
2025, 41(1): 118-126. DOI: 10.12449/JCH250118
Abstract(154) HTML (2020) PDF (877KB)(16)
Abstract:
Objective To investigate the general situation， dietary factors， and clinical features of patients with recurrent primary common bile duct stones， and to provide a basis for effective prevention of stone recurrence. Methods A retrospective analysis was performed for 23 730 patients who underwent cho...
Case Report
POEMS syndrome with hepatosplenomegaly as the initial manifestation: A report of two cases
Ye ZHANG, Wenqing WANG, Jing LI, Qianrong BAI, Jiayu LI, Yan CHENG, Miaomiao FANG, Nana GAO, Changxing HUANG
2025, 41(1): 127-132. DOI: 10.12449/JCH250119
Abstract(140) HTML (68) PDF (2190KB)(26)
Abstract:
POEMS syndrome is a rare condition associated with plasma cell disorders， and it often involves multiple systems and has diverse clinical manifestations. This article reports two cases of POEMS syndrome with hepatosplenomegaly as the initial manifestation. During the course of the disease， the patie...
Review
Application of health-related quality of life assessment in patients with chronic hepatitis B and related advances
Fei HUANG, Meifang HAN
2025, 41(1): 133-140. DOI: 10.12449/JCH250120
Abstract(164) HTML (1632) PDF (763KB)(41)
Abstract:
The transformation of traditional biomedical model into the bio-psycho-social medical model means that the purpose of clinical diagnosis and treatment not only focuses on the disease itself， but also emphasizes the quality of life and happiness index of patients. Since chronic hepatitis B （CHB） is i...
Application of machine learning in the diagnosis and treatment of chronic hepatitis C
Hua HAN, Zhongping DUAN, Yang WANG
2025, 41(1): 141-144. DOI: 10.12449/JCH250121
Abstract(142) HTML (68) PDF (533KB)(23)
Abstract:
With the development of artificial intelligence， machine learning has shown great potential in the field of medical health. Machine learning conducts a comprehensive analysis of patient data including clinical features， blood tests， and imaging examinations and establishes corresponding mathematical...
Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis
Aifang LIU, Lei LUO, Wenlong YANG
2025, 41(1): 145-150. DOI: 10.12449/JCH250122
Abstract(237) HTML (1170) PDF (1374KB)(86)
Abstract:
Metabolic dysfunction-associated steatotic liver disease is the largest liver disease around the world and is a serious public health hazard， but there has always been a lack of drugs approved for treatment. On March 14， 2024， Resmetirom became the first drug approved by the US Food and Drug Adminis...
Research advances in the association of adipokines with metabolic associated fatty liver disease and its associated liver cancer
Yixiao ZHANG, Jianguang SUN, Bowen JIANG
2025, 41(1): 151-158. DOI: 10.12449/JCH250123
Abstract(146) HTML (92) PDF (1450KB)(23)
Abstract:
With the emergence of unhealthy dietary structures in people’s life， metabolic associated fatty liver disease （MAFLD） has gradually become the most important chronic liver disease in China， and there is also a gradual increase in the cases of MAFLD-associated liver cancer. Adipose tissue not only ha...
Role of dynamin-related protein 1 in non-alcoholic fatty liver disease
Haishan SHEN, Shuo WANG, Gong FENG
2025, 41(1): 159-163. DOI: 10.12449/JCH250124
Abstract(153) HTML (95) PDF (803KB)(26)
Abstract:
The morphological changes and functions of mitochondria are closely associated with the development and progression of non-alcoholic fatty liver disease （NAFLD）. Dynamin-related protein 1 （Drp1） is one of the primary proteins determining mitochondrial fission， and its activity is strictly controlled...
Association of the adipokine Chemerin with the development and progression of liver fibrosis
Xinyuan ZHANG, Nuoqi ZHANG, Guohui YU, Wenshuai REN, Yaling WANG
2025, 41(1): 164-169. DOI: 10.12449/JCH250125
Abstract(150) HTML (78) PDF (950KB)(20)
Abstract:
Liver fibrosis is the common pathological process in the progression of various chronic liver diseases to liver cirrhosis， and it greatly affects the prognosis of patients with chronic liver diseases. As a novel adipokine， Chemerin participates in the metabolism of glucose and lipids and inflammatio...
Molecular mechanisms of traditional Chinese medicine in reversing liver fibrosis
Xiaoling GUO, Zhansheng JIA, Jing ZHANG
2025, 41(1): 170-175. DOI: 10.12449/JCH250126
Abstract(245) HTML (1473) PDF (917KB)(64)
Abstract:
Liver fibrosis is the intermediate stage in the progression of many chronic liver diseases to liver cirrhosis， and although there is still a lack of widely accepted and effective chemical or biological agents for reversing liver fibrosis， significant progress has been made in the treatment of liver ...
Diagnosis and treatment of cirrhotic portal hypertension with spontaneous portosystemic shunt: Current status and prospects
Yaxin CHEN, Wen GUO, Kaige LIU, Qian LI, Mingxin ZHANG
2025, 41(1): 176-182. DOI: 10.12449/JCH250127
Abstract(145) HTML (1258) PDF (1386KB)(28)
Abstract:
Liver cirrhosis is the terminal stage of various chronic liver diseases， with the main clinical manifestation of portal hypertension， which can lead to spontaneous portosystemic shunt （SPSS）. SPSS is very common in clinical practice and is closely associated with the prognosis of patients. This arti...
Research advances in liver venous deprivation
Bensong HE, Ming XIAO, Qijia ZHANG, Canhong XIANG, Yanxiong WANG, Yingbo LI, Zhishuo WANG
2025, 41(1): 183-188. DOI: 10.12449/JCH250128
Abstract(132) HTML (1736) PDF (664KB)(21)
Abstract:
Portal vein embolization （PVE） can induce atrophy of the embolized lobe and compensatory regeneration of the non-embolized lobe. However， due to inadequate regeneration of future liver remnant （FLR） after PVE， some patients remain unsuitable for hepatectomy after PVE. In recent years， liver venous d...
Research advances in pancreaticobiliary maljunction
Xiaoxuan TANG, Lei WANG, Bin ZHANG
2025, 41(1): 189-194. DOI: 10.12449/JCH250129
Abstract(186) HTML (59) PDF (742KB)(48)
Abstract:
Pancreaticobiliary maljunction （PBM） is a rare congenital developmental defect of the biliary-pancreatic system characterized by a junction of the pancreatic and bile ducts outside the duodenal wall， forming an extended common channel. This anatomical anomaly compromises the normal function of Oddi’...
Introduction of High - quality Articles in Foreign Journals
The New England Journal of Medicine｜Xalnesiran with or without an immunomodulator in chronic hepatitis B
2025, 41(1): 62-62. DOI: 10.12449/JCH2501.gwqkjpwzjj1
Abstract(110) HTML (62) PDF (952KB)(17)
Abstract:
Journal of Hepatology｜Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic
2025, 41(1): 182-182. DOI: 10.12449/JCH2501.gwqkjpwzjj2
Abstract(99) HTML (74) PDF (960KB)(12)
Abstract:
Acknowledgements
Current reviewers
2025, 41(1): 150-150. DOI: 10.12449/JCH2501.zhixie
Abstract(95) HTML (62) PDF (935KB)(6)
Abstract:
    

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

YesterdayIP[2720]YesterdayPV[5120]TodayIP[1095]TodayPV[1951]Online[186]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd